Research programme: alpha GABA receptor neuromodulators - RespireRx Pharmaceuticals/University of Wisonsin Milwoukee
Alternative Names: GABA(A) receptor allosteric neuromodulators - University of Wisconsin MilwaukeeLatest Information Update: 28 May 2025
At a glance
- Originator University of Wisconsin at Milwaukee
- Developer RespireRx Pharmaceuticals; University of Wisconsin at Milwaukee
- Class 3-ring heterocyclic compounds; Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Benzodiazepines; Imidazoles; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Depressive disorders; Epilepsy; Migraine; Pain; Trigeminal neuralgia
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Depressive disorders in USA
- 28 May 2025 No recent reports of development identified for preclinical development in Pain in USA
- 28 Apr 2024 No recent reports of development identified for preclinical development in Anxiety-disorders in USA